DTP Vaccines Global Market Report 2024

Diphtheria, Tetanus, Pertussis (DTP) vaccines are combination vaccines administered intramuscularly to safeguard children under the age of 7 from diphtheria, tetanus, and whooping cough. These vaccines play a crucial role in conferring immunity to three bacterial diseases - diphtheria, tetanus, and pertussis - all of which can be life-threatening.

The primary product categories within DTP vaccines are DTaP, TD, and Tdap. DTaP vaccines are designed to help children under seven years of age develop immunity against three potentially deadly bacterial infections, diphtheria, pertussis (whooping cough), and tetanus. The diseases covered by these vaccines include diphtheria, pertussis, and tetanus, and they are administered in various healthcare settings such as hospitals, clinics, and vaccination centers.

The DTP vaccines market research report is one of a series of new reports from The Business Research Company that provides DTP vaccines market statistics, including global market size, regional shares, competitors with a DTP vaccines market share, detailed DTP vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the DTP vaccines industry. This DTP vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dtp vaccines market size has grown strongly in recent years. It will grow from $6.13 billion in 2023 to $6.56 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth observed in the historical period can be credited to an increase in access to healthcare, sustained efforts for protection against infectious diseases, and a rising awareness of immunization.

The dtp vaccines market size is expected to see strong growth in the next few years. It will grow to $8.63 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be ascribed to the presence of a robust late-stage pipeline and the approval of new drugs, a rise in healthcare expenditure, and the implementation of immunization policies aimed at eradicating endemic diseases. Notable trends in the forecast period encompass a concentration on the development of combination vaccines, substantial investment in research and development activities, the utilization of artificial intelligence (AI) in vaccine development, and a strategic focus on acquisitions.

Governments worldwide are actively endorsing the development of DTP vaccines to curb the spread of the disease. Initiatives such as India's Universal Immunization Program, designed to provide recommended vaccines, including those against tuberculosis, polio, diphtheria, tetanus, and whooping cough, for all children in the country, contribute to regular vaccination drives. These efforts are anticipated to have a positive impact on market growth in the forecast period.

The anticipated rise in healthcare expenditure is set to propel the DTP vaccine market's growth. Healthcare expenditure encompasses the total financial outlay on healthcare goods and services, covering medical equipment, hospital services, physician services, prescription drugs, and public health activities. Increased healthcare spending plays a pivotal role in fostering an environment conducive to the development, production, distribution, and effective utilization of DTP vaccines. For instance, according to the Office for National Statistics in May 2023, the UK experienced a 9.4% increase in nominal healthcare spending and a 9.7% rise in real terms. The total healthcare expenditure in the UK reached $367.25 billion (£280.7 billion) in 2021, with pharmaceutical spending at $51.84 billion (£39.6 billion). Additionally, preventive care spending surged to $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Consequently, the upswing in healthcare expenditure is a driving force behind the expansion of the DTP vaccine market.

Prominent companies in the diphtheria, tetanus, and pertussis (DTP) vaccine market are dedicated to developing innovative vaccines such as BOOSTRIX to establish a competitive advantage. BOOSTRIX, introduced by GSK PLC, a UK-based biotechnology and pharmaceutical company, is a vaccine designed to protect adolescents (ages 10-18) and adults from diseases caused by Bordetella pertussis, diphtheria, and tetanus bacteria. As a combination vaccine, BOOSTRIX safeguards against whooping cough (pertussis), diphtheria, and tetanus. GSK plc received approval from the US Food and Drug Administration (FDA) for BOOSTRIX in October 2022, making it the first vaccine licensed specifically for use by pregnant women to shield unborn children from illness. Administered during pregnancy, it enhances the mother's antibodies, providing protection to the growing baby.

Companies within the DTP vaccines market are increasingly investing in the production of DTP combination vaccines, streamlining the immunization process against infectious diseases by reducing the need for multiple vaccination shots. Various DTP combination vaccines, such as tetravalent (DTP-HepB), pentavalent (DTP-HepB-Hib), and hexavalent (DTP-Hib-HepB-IPV), offer equivalent protection compared to individual vaccines administered separately.

In August 2022, GSK plc executed a significant acquisition by purchasing Affinivax, Inc., a US-based biotechnology company, for $2.1 billion. This strategic move reinforces GSK's commitment to building a robust portfolio of specialized drugs and vaccines. Among the acquired assets is AFX3772, a candidate for the next-generation 24-valent pneumococcal vaccine, utilizing the groundbreaking Multiple Antigen Presenting System (MAPSTM) platform technology, currently in phase II development. Affinivax, Inc. specializes in developing preventative and therapeutic vaccines using an innovative approach to vaccine technology.

Major companies operating in the dtp vaccines market report are GlaxoSmithKline, Sanofi, Merck & Co Inc., Meiji Holdings Co., Ltd., Shenzhen Kangtai Biological Products, Serum Institute of India Pvt Ltd., Sun Pharmaceutical Industries Ltd., AJ Vaccines, PT Bio Farma, Bio Med, Sinergium Biotech SA, Teuto Brasileiro, Amgen, Roche, BioFabri, Sinopharm, Chongqing Zhifei, Hualan Biological Engineering Inc., Ezequiel Dias Foundation (FUNED), BioKangtai, Uniao Quimica, Valneva SE, The Abu Dhabi Health Services Company (SEHA), ImevaX GmbH, Cristalia, Bharat Biotech, Bio-Manguinhos-Institute of Technology on Immunobiologicals, Connaught Laboratories Inc., Biolab Farmaceutica, Massbiologics, Beijing Tiantan Biological Products Co Ltd., Butantan Institute, C.R.I. Kasauli, Bayer, Pfizer, Abbott Laboratories, Serum Institute of India Pvt Ltd., Novartis, Wyeth-Ayerst, Dano Vaccines, Merck Serono Middle East, Hypermarcas, AstraZeneca, Grifols, Sinovac Biotech Ltd., AbbVie Inc., Apotex, GreenSignal Bio Pharma Private Limited (GSBPL), Teva Pharmaceutical Industries Ltd F. Hoffmann-La Roche AG, Boehringer Ingelheim, CanSino Biologics, Gilead Sciences, Panacea Biotec Ltd., Fiocruz, Johnson & Johnson, Walvax biotechnology, BioNTech, EMS Pharma, Mylan, National Administration of Laboratories and Institutes of Health (ANLIS), Zentiva, Afrigen Biologics & Vaccines

North America was the largest region in the DTP vaccines market in 2023. The regions covered in the dtp vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the dtp vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The DTP vaccine market consists of sales of Daptacel, Infanrix, Kinrix, Paediarix, Pentacel, Quadracel, and Vaxelis vaccines. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

DTP Vaccines Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dtp vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dtp vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dtp vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Blood Glucose Test Strips; Insulin Pens, Syringes, Pumps And Injectors; Lancing Devices And Equipment; Continuous Glucose Monitoring Devices And Equipment; Blood Glucose Meters
• 2) By Type of Expenditure: Public; Private
• 3) By Product: Instruments Or Equipment; Disposables
• 4) By Type Of Testing: Point Of Care (POC) Testing; Non-Point Of Care (POC) Testing
• 5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
• Subsegments Covered: Glucose Dehydrogenase; Glucose Oxidase; Pens; Injectors And Pumps; Syringes
• Companies Mentioned: GlaxoSmithKline; Sanofi; Merck & Co Inc; Meiji Holdings Co., Ltd; Shenzhen Kangtai Biological Products
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.